Formation and plasticity of GABAergic synapses:: physiological mechanisms and pathophysiological implications

被引:250
作者
Fritschy, JM [1 ]
Brünig, I [1 ]
机构
[1] Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland
关键词
GABA(A) receptor; gephyrin; synaptic clustering; neurosteroid; temporal lobe epilepsy; benzodiazepine;
D O I
10.1016/S0163-7258(03)00037-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
gamma-Aminobutyric acidA (GABA(A)) receptors mediate most of the fast inhibitory neurotransmission in the CNS. They represent a major site of action for clinically relevant drugs, such as benzodiazepines and ethanol, and endogenous modulators, including neuroactive steroids. Alterations in GABA(A) receptor expression and function are thought to contribute to prevalent neurological and psychiatric diseases. Molecular cloning and immunochemical characterization of GABA(A) receptor subunits revealed a multiplicity of receptor subtypes with specific functional and pharmacological properties. A major tenet of these studies is that GABA(A) receptor heterogeneity represents a key factor for fine-tuning of inhibitory transmission under physiological and pathophysiological conditions. The aim of this review is to highlight recent findings on the regulation of GABA(A) receptor expression and function, focusing on the mechanisms of sorting, targeting, and synaptic clustering of GABA(A) receptor subtypes and their associated proteins, on trafficking of cell-surface receptors as a means of regulating synaptic (and extrasynaptic) transmission on a short-time basis, on the role of endogenous neurosteroids for GABA(A) receptor plasticity, and on alterations of GABA(A) receptor expression and localization in major neurological disorders. Altogether, the findings presented in this review underscore the necessity of considering GABA(A) receptor-mediated neurotransmission as a dynamic and highly flexible process controlled by multiple mechanisms operating at the molecular, cellular, and systemic level. Furthermore, the selected topics highlight the relevance of concepts derived from experimental studies for understanding GABA(A) receptor alterations in disease states and for designing improved therapeutic strategies based on subtype-selective drugs. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:299 / 323
页数:25
相关论文
共 248 条
[1]   α4β3δ GABAA receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential [J].
Adkins, CE ;
Pillai, GV ;
Kerby, J ;
Bonnert, TP ;
Haldon, C ;
McKernan, RM ;
Gonzalez, JE ;
Oades, K ;
Whiting, PJ ;
Simpson, PB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :38934-38939
[2]   Chronic benzodiazepine treatment of cells expressing recombinant GABAA receptors uncouples allosteric binding:: studies on possible mechanisms [J].
Ali, NJ ;
Olsen, RW .
JOURNAL OF NEUROCHEMISTRY, 2001, 79 (05) :1100-1108
[3]  
Allison DW, 1998, J NEUROSCI, V18, P2423
[4]   Alterations of hippocampal GABAergic system contribute to development of spontaneous recurrent seizures in the rat lithium-pilocarpine model of temporal lobe epilepsy [J].
André, V ;
Marescaux, C ;
Nehlig, A ;
Fritschy, JM .
HIPPOCAMPUS, 2001, 11 (04) :452-468
[5]   Postsynaptic clustering of γ-aminobutyric acid type A receptors by the γ3 subunit in vivo [J].
Baer, K ;
Essrich, C ;
Benson, JA ;
Benke, D ;
Bluethmann, H ;
Fritschy, JM ;
Lüscher, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12860-12865
[6]   Modulation of the expression of GABAA receptors in rat cerebellar granule cells by protein tyrosine kinases and protein kinase C [J].
Balduzzi, R ;
Cupello, A ;
Robello, M .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2002, 1564 (01) :263-270
[7]   Ethanol markedly increases "GABAergic'' neurosteroids in alcohol-preferring rats [J].
Barbaccia, ML ;
Affricano, D ;
Trabucchi, M ;
Purdy, RH ;
Colombo, G ;
Agabio, R ;
Gessa, GL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 384 (2-3) :R1-R2
[8]  
Barbaccia ML, 2001, INT REV NEUROBIOL, V46, P243
[9]  
Barnard EA, 1998, PHARMACOL REV, V50, P291
[10]  
BARNARD EA, 2001, HANDB EXP PHARM, V150, P79